The effect of combined steroid and calcium channel blocker injection on human hypertrophic scars in animal model: A new strategy for the treatment of hypertrophic scars

Dermatologic Surgery

Volumn 36, Issue 12, 2010, Pages 1942-1949

  Yang, Jui Yung ^a   Huang, Chun Yuan ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; DECORIN; EPIDERMAL GROWTH FACTOR RECEPTOR; SODIUM CHLORIDE; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRIAMCINOLONE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURN PATIENT; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN TISSUE; HYPERTROPHIC SCAR; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN FIBROBLAST; TREATMENT DURATION;

ANIMALS; BURNS; CALCIUM CHANNEL BLOCKERS; CELL PROLIFERATION; CICATRIX, HYPERTROPHIC; DECORIN; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FIBROBLASTS; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, NUDE; STATISTICS, NONPARAMETRIC; TRIAMCINOLONE; VERAPAMIL;

EID: 78649985814     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01759.x     Document Type: Article

References (35)

1. Burd A, Huang L., Hypertrophic response and keloid diathesis: two very different forms of scar. Plast Reconstr Surg 2005; 116: 150e-7e.
2. Armour A, Scott P, Edward E., Cellular and molecular pathology of HTS: basis for treatment. Wound Rep Reg 2007; 15: S6-17.
3. Gira AK, Brown LF, Washington CV, et al,. Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol 2004; 50: 850-3.
4. Sayani K, Dodd CM, Nedelec B, et al,. Delayed appearance of decorin in healing burn scars. Histopathology 2000; 36: 262-72.
5. Kose O, Waseem A., Keloids and hypertrophic scars: are they two different sides of the same coin? Dermatol Surg 2008; 34: 336-46.
6. Dabiri G, Campaner A, Morgan JR, et al,. A TGF-beta1-dependent autocrine loop regulates the structure of focal adhesions in hypertrophic scar fibroblasts. J Invest Dermatol 2006; 126: 963-70.
7. Sheridan RL, Tompkins RG., What's new in burns and metabolism. J Am Coll Surg 2004; 198: 243-63.
8. Wolfram D, Tzankov A, Pulzl P, et al,. Hypertrophic scars and keloids-a review of their pathophysiology, risk factors, and therapeutic management. Dermatol Surg 2009; 35: 171-81.
9. Scott PG, Dodd CM, Tredget EE, et al,. Chemical characterization and quantification of proteoglycans in human post-burn hypertrophic and mature scars. Clin Sci (London) 1996; 90: 417-25.
10. Scott PG, Dodd CM, Ghahary A, et al,. Fibroblasts from post-burn hypertrophic scar tissue synthesize less decorin than normal dermal fibroblasts. Clin Sci (London) 1998; 94: 541-7.
11. Stewart JE, Wheatley DN, Holmes JD, et al,. Purification and identification of a human dermal extract component inhibitory to fibroblast proliferation. Cell Biol Int 2001; 25: 607-12.
12. De Luca A, Santra M, Baldi A, et al,. Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. J Biol Chem 1996; 271: 18961-5.
13. Zhang Z, Li XJ, Liu Y, et al,. Recombinant human decorin inhibits cell proliferation and downregulates TGF-beta1 production in hypertrophic scar fibroblasts. Burns 2007; 33: 634-41.
14. Wang XQ, Liu YK, Qing C, et al,. A review of the effectiveness of antimitotic drug injections for hypertrophic scars and keloids. Ann Plast Surg 2009; 63: 688-92.
15. Doong H, Dissanayake S, Gowrishankar TR, et al,. The 1996 Lindberg Award. Calcium antagonists alter cell shape and induce procollagenase synthesis in keloid and normal human dermal fibroblasts. J Burn Care Rehabil 1996; 17: 497-514.
16. D'Andrea F, Brongo S, Ferraro G, et al,. Prevention and treatment of keloids with intralesional verapamil. Dermatology 2002; 204: 60-2.
17. Copcu E, Sivrioglu N, Oztan Y., Combination of surgery and intralesional verapamil injection in the treatment of the keloid. J Burn Care Rehabil 2004; 25: 1-7.
18. Margaret Shanthi FX, Ernest K, Dhanraj P., Comparison of intralesional verapamil with intralesional triamcinolone in the treatment of hypertrophic scars and keloids. Indian J Dermatol Venereol Leprol 2008; 74: 343-8.
19. Mustoe TA, Cooter RD, Gold MH, et al,. International clinical recommendations on scar management. Plast Reconstr Surg 2002; 110: 560-71.
20. Morris DE, Wu L, Zhao LL, et al,. Acute and chronic animal models for excessive dermal scarring: quantitative studies. Plast Reconstr Surg 1997; 100: 674-81.
21. Zhu KQ, Engrav LH, Gibran NS, et al,. The female, red Duroc pig as an animal model of hypertrophic scarring and the potential role of the cones of skin. Burns 2003; 29: 649-64.
22. Shetlar MR, Shetlar CL, Kischer CW, et al,. Implants of keloid and hypertrophic scars into the athymic nude mouse: changes in the glycosaminoglycans of the implants. Connect Tissue Res 1991; 26: 23-36.
23. Yang DY, Li SR, Wu JL, et al,. Establishment of a hypertrophic scar model by transplanting full-thickness human skin grafts onto the backs of nude mice. Plast Reconstr Surg 2007; 119: 104-9; discussion 10-1.
24. Kischer CW, Pindur J, Shetlar MR, et al,. Implants of hypertrophic scars and keloids into the nude (athymic) mouse: viability and morphology. J Trauma 1989; 29: 672-7. (Pubitemid 19156503)
25. Shetlar MR, Shetlar DJ, Bloom RF, et al,. Involution of keloid implants in athymic mice treated with pirfenidone or with triamcinolone. J Lab Clin Med 1998; 132: 491-6.
26. Muir IF, Padilla-Lamb A, Stewart JE, et al,. Growth inhibition of cultured fibroblasts by extracts from human dermis. Br J Plast Surg 1997; 50: 186-93.
27. Lee RC, Doong H, Jellema AF., The response of burn scars to intralesional verapamil. Report of five cases. Arch Surg 1994; 129: 107-11.
28. Niessen FB, Spauwen PH, Schalkwijk J, et al,. On the nature of hypertrophic scars and keloids: a review. Plast Reconstr Surg 1999; 104: 1435-58.
29. Boyadjiev C, Popchristova E, Mazgalova J., Histomorphologic changes in keloids treated with Kenacort. J Trauma 1995; 38: 299-302.
30. Bjornson Granqvist A, Ebefors K, Saleem MA, et al,. Podocyte proteoglycan synthesis is involved in the development of nephrotic syndrome. Am J Physiol Renal Physiol 2006; 291: F722-30.
31. Kydd AS, Reno CR, Tsao HW, et al,. Early inflammatory arthritis in the rabbit: the influence of intraarticular and systemic corticosteroids on mRNA levels in connective tissues of the knee. J Rheumatol 2007; 34: 130-9.
32. Yeo TK, Brown L, Dvorak HF., Alterations in proteoglycan synthesis common to healing wounds and tumors. Am J Pathol 1991; 138: 1437-50.
33. Feugaing DD, Tammi R, Echtermeyer FG, et al,. Endocytosis of the dermatan sulfate proteoglycan decorin utilizes multiple pathways and is modulated by epidermal growth factor receptor signaling. Biochimie 2007; 89: 637-57.
34. Rosen LB, Greenberg ME., Stimulation of growth factor receptor signal transduction by activation of voltage-sensitive calcium channels. Proc Natl Acad Sci U S A 1996; 93: 1113-8.
35. Ghahary A, Shen YJ, Scott PG, et al,. Immunolocalization of TGF-beta 1 in human hypertrophic scar and normal dermal tissues. Cytokine 1995; 7: 184-90.